(secondQuint)Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer.

 Docetaxel plus gemcitabine is an active combination in the salvage treatment for metastatic breast cancer.

 Administered every two weeks, this combination has a favorable toxicity profile, and promising activity in > 1st line treatment for metastatic breast cancer.

 Recently, initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab demonstrated prolonged progression-free survival, as compared with paclitaxel alone.

 This study will evaluate the addition of bevacizumab to a biweekly regimen of docetaxel and gemcitabine in the salvage therapy for metastatic breast cancer.

.

 Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer@highlight

This study will evaluate the efficacy and toxicity of docetaxel, gemcitabine and bevacizumab combination, administered biweekly, as salvage treatment in patients with metastatic and HER2 negative breast cancer.

